• Home
  • Technology
  • Gaming
  • Entertainment
  • World & Business
  • Science
  • Sports
  • AI
HomeTechnologyGamingEntertainmentWorld & BusinessScienceSportsAI
  • HomeTechnologyGamingEntertainmentWorld & BusinessScienceSportsAI
    • Home
    • Technology
    • Gaming
    • Entertainment
    • World & Business
    • Science
    • Sports
    • AI
    AI

    Jason Pontin Finds LLMs Unimpressive

    Investor and former MIT Technology Review chief posted the remark in a thread with Gary Marcus.

    JP
    1 Source, 29d ago, first seen 29d ago

    TLDR

    Jason Pontin replied on the platform that he remains in awe of proprietary biology models yet finds himself unimpressed at some deep level by the LLMs. The post, addressed to Gary Marcus and two other accounts, comes from the general partner at DCVC who cofounded Totus Medicines and chairs or serves on boards of AI biotech firms. Pontin previously served as editor in chief and CEO of MIT Technology Review. The packet records only this single reply and the account details supplied with it.

    Combined views

    2.5K

    1 Source, first seen 29d ago

    Combined views

    2.5K

    1 Source, first seen 29d ago

    7 likes
    7 likes
    2 comments
    1 saves
    1 reposts

    Sentiment

    Positive——Negative

    Summary

    Not enough discussion yet.

    No sentiment analysis available yet.

    2 comments
    1 saves
    1 reposts

    Sentiment

    Positive——Negative

    Summary

    Not enough discussion yet.

    No sentiment analysis available yet.

    Today's Rank

    —

    Not ranked yet

    Today's Rank

    —

    Not ranked yet

    1 Source

    @jason_pontin@GaryMarcus @proximabio @anilkseth As someone who uses these models, I’m in awe of the proprietary biology models—but unimpressed at some deep level by the LLMs.

    1 Source

    @jason_pontin@GaryMarcus @proximabio @anilkseth As someone who uses these models, I’m in awe of the proprietary biology models—but unimpressed at some deep level by the LLMs.